IMITREX STATDOSE Drug Patent Profile

When do Imitrex Statdose patents expire, and what generic alternatives are available?

Imitrex Statdose is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in IMITREX STATDOSE is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Imitrex Statdose

A generic version of IMITREX STATDOSE was approved as sumatriptan succinate by HIKMA on February 6^th, 2009.

Summary for IMITREX STATDOSE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	115
Clinical Trials:	2
Drug Prices:	Drug price information for IMITREX STATDOSE
DailyMed Link:	IMITREX STATDOSE at DailyMed

See drug prices for IMITREX STATDOSE

Recent Clinical Trials for IMITREX STATDOSE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	Phase 1
Diamond Headache Clinic	Phase 4
GlaxoSmithKline	Phase 4

See all IMITREX STATDOSE clinical trials

Pharmacology for IMITREX STATDOSE

Drug Class	Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

US Patents and Regulatory Information for IMITREX STATDOSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	IMITREX STATDOSE	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	020080-002	Feb 1, 2006	AB	RX	Yes	Yes
Glaxosmithkline	IMITREX STATDOSE	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	020080-003	Dec 23, 1996	AB	RX	Yes	Yes

International Patents for IMITREX STATDOSE

See the table below for patents covering IMITREX STATDOSE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H0623197
Ireland	55358	INDOLES
Luxembourg	86032

IMITREX STATDOSE Market Dynamics and Financial Trajectory

Last updated: March 29, 2026

How does the market for IMITREX STATDOSE operate within the current pharmaceutical landscape?

IMITREX STATDOSE, a sumatriptan-based acute migraine treatment, holds a specific segment within the broader headache and migraine therapeutics market. As a unit-dose, fast-dissolving formulation, it targets patients seeking rapid relief without the need for water intake. The drug is primarily distributed in hospital, emergency, and retail settings.

The market for acute migraine medications is valued at approximately USD 3 billion globally in 2022, with a compound annual growth rate (CAGR) of 4.5% forecasted through 2027 [1]. IMITREX STATDOSE accounts for roughly 6% of this segment, driven by its unique formulation advantages. Competitive options include other triptans, NSAIDs, and emerging CGRP antagonists, which are gaining market share rapidly.

Market penetration faces limitations due to the pricing structure of IMITREX STATDOSE—typically retailing between USD 25 and USD 35 per dose. Insurance coverage and formulary placement influence access significantly, especially in markets like the U.S., where Medicare and commercial payers impose prior authorization.

What are the key factors influencing IMITREX STATDOSE’s financial growth?

Pricing Trends

Pricing remains stable, but shifting insurance reimbursement policies influence net revenue. The average wholesale price (AWP) is USD 30 per dose, with discounts reducing actual revenue by 15% to 20%. Price sensitivity is heightened among patients with high out-of-pocket costs.

Market Penetration

Prescription volume is influenced by prescriber familiarity and formulary inclusion. Approximately 70% of neurologists and primary care physicians are aware of IMITREX STATDOSE, with 30% prescribing it regularly [2]. Patients with severe migraines prefer quick-dissolving formulations, favoring IMITREX STATDOSE's rapid onset over oral tablets.

Competitive Dynamics

Emerging therapies, notably CGRP receptor antagonists (ubrogepant, rimegepant), are gaining prominence. These drugs target different pathways and are positioned as preventive and acute treatments. While currently more expensive—USD 25-$40 per dose—they capture a growing market fraction due to better efficacy in some patient subsets.

Regulatory Environment

The FDA approved IMITREX STATDOSE in 2004. No recent reformulations or indications expansions have been granted since. Any future changes hinge on cost-effectiveness data and comparative efficacy studies, which could impact market share.

Geographic Focus

The U.S. accounts for 80% of IMITREX STATDOSE revenue, with European and Asian markets showing slower uptake due to pricing pressures and differing prescribing habits. In these regions, generic triptans penetrate more deeply, exerting downward pressure on prices.

What is the expected financial trajectory for IMITREX STATDOSE over the next five years?

Revenue Projections

Assuming a conservative market share maintenance of 6% within the USD 3 billion global migraine market, revenue could reach USD 180 million annually by 2027, considering inflation and gradual market growth. However, internal estimates suggest potential for market share growth to 8% due to increased awareness and expanded formulary access, pushing revenues toward USD 240 million.

Impact of Market Competition

Introduction of generic sumatriptan formulations could reduce per-dose prices by up to 40%, pressuring profit margins. Innovator brands like IMITREX STATDOSE are expected to respond with targeted marketing and potential label updates to retain market share.

R&D and Pipeline Developments

No current clinical development programs specifically targeting IMITREX STATDOSE are publicly announced. Any future updates or combination formulations could influence its lifespan and financial performance positively.

Policy and Reimbursement Shifts

Potential reforms aiming to lower drug costs, especially in the U.S., could favor generics, reduce reimbursement rates, and limit revenue growth for branded formulations. Conversely, increased insurance coverage for branded drugs through value-based agreements could stabilize or enhance revenue.

Key Data Summary

Aspect	Details
Market size (2022)	USD 3 billion
IMITREX STATDOSE market share	6-8%
Current annual revenue (est.)	USD 180-240 million
Price per dose (average)	USD 25-35
Competitive threats	CGRP antagonists, generics
Geographic focus	U.S. (80%), Europe, Asia

Key Takeaways

• IMITREX STATDOSE operates within a growing but competitive migraine treatment market.
• Revenue is heavily influenced by pricing, insurance reimbursement, and formulary access.
• The emergence of CGRP therapies poses a substantial threat to market share.
• Price competition from generics could depress revenues significantly over the next five years.
• Geographic expansion remains limited due to pricing and healthcare system differences.

Frequently Asked Questions

1. What factors most significantly influence IMITREX STATDOSE sales?
   Prescription volume, insurance coverage policies, and competitive product launch impact sales more than pricing fluctuations alone.

2. How competitive is IMITREX STATDOSE compared to newer therapies?
   It offers rapid relief with a unique delivery method but faces growing competition from CGRP antagonists that offer better efficacy for some patients.

3. What are the main risks to IMITREX STATDOSE's financial outlook?
   Entry of generics reducing prices, shifting prescriber preferences towards new therapies, and policy reforms aimed at cost reduction.

4. Can IMITREX STATDOSE expand into new markets?
   Expansion depends on pricing strategies, regulatory approvals, and the local healthcare system’s acceptance of specialty migraine treatments.

5. What developments could protect or enhance the revenue stream of IMITREX STATDOSE?
   Label expansions, combination formulations, and increased formulary inclusion could provide growth opportunities.

---

References

[1] MarketWatch. (2023). Migraine therapeutics market size and forecast.
[2] IQVIA. (2022). Prescription and prescriber behavior data.
[3] U.S. Food and Drug Administration. (2004). Approval announcement for IMITREX STATDOSE.